Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

serotonin/iiveldus

Link salvestatakse lõikelauale
12 tulemused
1. INTRODUCTION The present invention relates to a novel method of controlling nausea and vomiting (or emesis) in mammals utilizing certain substituted-phenylalkylamino (and aminoacid) derivatives which do not exhibit certain side effects of the type attributable to dopamine blocking compounds which

Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS-REFERENCE TO RELATED APPLICATION This application claims, under 35 U.S.C. .sctn.119(a), the benefit of Korean Patent Application No. 10-2007-0084322 filed Aug. 22, 2007, the entire contents of which are incorporated herein by reference. BACKGROUND OF THE INVENTION 1. Field of the Invention The

Methods for treating emesis and nausea using optically pure R(+) ondansetron

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION This invention relates to novel compositions of matter containing optically pure R(+) ondansetron. These novel compositions have potent antiemetic activity and are useful in ameliorating the nausea and vomiting otherwise induced by cancer chemotherapeutic agents and

4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This application claims the benefit of Provisional Application 60/069,890 Jan. 5, 1996. The present invention is directed to certain novel compounds and their use as pharmaceutical agents having unique central nervous system activity. This invention relates to 4,5-dihydronaphth[1,2-c]isoxazoles and

Deuterium-enriched pyridinonecarboxamides and derivatives

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
SUMMARY OF THE INVENTION The present invention is concerned with deuterium-enriched pyridinone carboxamides and derivatives thereof of formula I, ##STR00002## Wherein, R.sub.1 and R.sub.2 are independently, H, D (deuterium with enrichment of 1%-100%), F, Cl, CD.sub.3 (methyl-d.sub.3),

Deuterium-enriched pyridinonecarboxamides and derivatives

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
SUMMARY OF THE INVENTION The present invention is concerned with deuterium-enriched pyridinonecarboxamides and derivatives thereof of formula 1, ##STR00002## Wherein, R.sub.1 and R.sub.2 are independently, H, D (deuterium with enrichment of 1%-100%), F, Cl, CD.sub.3 (methyl-d.sub.3),

Derivatives of amide analogs of certain methano bridged quinolizines

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This invention relates to novel amide derivatives of certain 2,6-methano-2H-quinolizines-type compounds, to the intermediates and processes for their preparation, to their ability to antagonize the effects of serotonin at the 5HT.sub.3 receptors, and to their end-use application in the treatment of

Methods for treating behavioral and other disorders using optically pure R(+) ondansetron

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION This invention relates to novel compositions of matter containing optically pure R(+) ondansetron. These novel compositions have potent antiemetic activity and are useful in ameliorating the nausea and vomiting otherwise induced by cancer chemotherapeutic agents and

Compositions using optically pure R(+) ondansetron

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION This invention relates to novel compositions of matter containing optically pure R(+) ondansetron. These novel compositions have potent antiemetic activity and are useful in ameliorating the nausea and vomiting otherwise induced by cancer chemotherapeutic agents and

Method treating cognitive disorders using optically pure R(+) ondansetron

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION This invention relates to novel compositions of matter containing optically pure R(+) ondansetron. These novel compositions have potent antiemetic activity and are useful in ameliorating the nausea and vomiting otherwise induced by cancer chemotherapeutic agents and

Cinnoline-3-carboxylic acid derivatives

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION This invention relates to a cinnoline derivative which is pharmaceutically useful as an antagonist against serotonin 5-HT.sub.3 receptor, its pharmaceutically acceptable salts, its N-oxide derivatives or solvates thereof, and pharmaceutical compositions containing the

Cinnoline-3-carboxylic acid derivatives

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION This invention relates to a cinnoline derivative which is pharmaceutically useful as an antagonist against serotonin 5-HT.sub.3 receptor, its pharmaceutically acceptable salts, its N-oxide derivatives or solvates thereof, and pharmaceutical compositions containing the
Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge